Being A Successful Trader Just Got Easier…
From 10x Trading Champion Chuck Hughes comes the e-book helping thousands to survive the bear market, “Options trading Made Easy”!

Already full of tools and strategies for success, each copy now comes with a daily Trade of the Day, straight from Chuck to you!

Download your copy now!
>>>
Brett A. Pletcher, insider at Gilead Sciences

Brett A. Pletcher Insider Information


Brett Pletcher leads a group at Gilead that includes the government affairs and policy, public affairs, and legal organizations. In his role, he oversees our work to shape health policy and communicate the company’s perspective across external audiences. As General Counsel, he is also responsible for all of the company’s legal functions, including intellectual property, litigation and compliance efforts associated with the promotion of our products.

Before joining Gilead in 2005, Brett was a partner in the law firm of Gunderson Dettmer, LLP, where he provided corporate and securities services to emerging growth public and private companies as well as venture capital investors

Brett received his bachelor’s degree in economics and political science from the University of California, Riverside and earned his law degree from the University of California, Berkeley’s Boalt Hall School of Law.

He is a member of the California State Bar and a former member of the Nasdaq Listing and Hearing Review Council, and currently serves on the Advisory Board for the East Bay Community Law Center.

What is Brett A. Pletcher's net worth?

The estimated net worth of Brett A. Pletcher is at least $1.82 million as of March 11th, 2021. Mr. Pletcher owns 29,166 shares of Gilead Sciences stock worth more than $1,818,792 as of July 3rd. This net worth estimate does not reflect any other investments that Mr. Pletcher may own. Additionally, Mr. Pletcher receives an annual salary of $2,470,000.00 as EVP at Gilead Sciences. Learn More about Brett A. Pletcher's net worth.

How old is Brett A. Pletcher?

Mr. Pletcher is currently 53 years old. There are 6 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Taiyin Yang Ph.D., Exec. VP of Pharmaceutical Devel. & Manufacturing, who is 68 years old. Learn More on Brett A. Pletcher's age.

What is Brett A. Pletcher's salary?

As the EVP of Gilead Sciences, Inc., Mr. Pletcher earns $2,470,000.00 per year. There are 4 executives that earn more than Mr. Pletcher. The highest earning executive at Gilead Sciences is Mr. Daniel P. O'Day, Chairman & CEO, who commands a salary of $6,090,000.00 per year. Learn More on Brett A. Pletcher's salary.

How do I contact Brett A. Pletcher?

The corporate mailing address for Mr. Pletcher and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected] Learn More on Brett A. Pletcher's contact information.

Has Brett A. Pletcher been buying or selling shares of Gilead Sciences?

Brett A. Pletcher has not been actively trading shares of Gilead Sciences within the last three months. As an example of a recent trade by , on Sunday, July 3rd, 0 shares of BMO Capital Markets stock. Learn More on Brett A. Pletcher's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes John Cogan (Director), John Martin (Director), Johanna Mercier (Insider), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 32,996 shares worth more than $2,270,148.09. The most recent insider tranaction occured on March, 11th when EVP Brett A Pletcher sold 3,634 shares worth more than $211,644.16. Insiders at Gilead Sciences own 0.2 % of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 3/11/2022.

Brett A. Pletcher Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2022Sell3,634$58.24$211,644.16View SEC Filing Icon  
2/9/2022Sell1,691$63.89$108,037.99View SEC Filing Icon  
2/1/2022Sell14,061$68.54$963,740.94View SEC Filing Icon  
3/11/2021Sell1,486$63.36$94,152.9629,166View SEC Filing Icon  
2/10/2021Sell1,975$67.41$133,134.7528,832View SEC Filing Icon  
5/5/2020Sell13,210$79.23$1,046,628.3027,204View SEC Filing Icon  
3/10/2020Sell2,950$75.55$222,872.5017,594View SEC Filing Icon  
3/2/2020Sell10,441$70.88$740,058.0825,085View SEC Filing Icon  
2/10/2020Sell2,950$69.32$204,494.0027,640View SEC Filing Icon  
2/6/2020Sell5,000$68.18$340,900.0029,690View SEC Filing Icon  
1/3/2020Sell2,950$64.63$190,658.5020,014View SEC Filing Icon  
12/3/2019Sell5,900$65.77$388,043.0022,964View SEC Filing Icon  
11/25/2019Sell15,000$66.85$1,002,750.0032,064View SEC Filing Icon  
11/19/2019Sell10,000$64.91$649,100.0017,064View SEC Filing Icon  
11/5/2019Sell2,095$66.06$138,395.7017,826View SEC Filing Icon  
11/1/2019Sell4,000$64.52$258,080.0023,921View SEC Filing Icon  
10/28/2019Sell5,677$63.31$359,410.8721,521View SEC Filing Icon  
8/19/2019Sell608$64.35$39,124.8027,198View SEC Filing Icon  
7/23/2019Sell7,200$65.07$468,504.0034,398View SEC Filing Icon  
6/18/2019Sell5,816$68.75$399,850.0027,198View SEC Filing Icon  
See Full Table

Brett A. Pletcher Buying and Selling Activity at Gilead Sciences

This chart shows Brett A Pletcher's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $62.36
Low: $61.27
High: $62.43

50 Day Range

MA: $61.97
Low: $57.72
High: $65.01

2 Week Range

Now: $62.36
Low: $57.17
High: $74.12

Volume

5,207,656 shs

Average Volume

7,469,634 shs

Market Capitalization

$78.22 billion

P/E Ratio

17.42

Dividend Yield

4.68%

Beta

0.38
The Safest Way To Start Trading Is Here!
One look at Wall Street right now and anyone can tell: it’s a mess! But new trades can get an edge with “Options Trading Made Easy” by trading champion Chuck Hughes, the best guide to options trading in the modern market.

Start with a small investment today and see where you can go!

Get your copy now!
>>>